Emergency hormonal contraception is used to prevent unintended pregnancy postcoitally. The mechanism of action of the most frequently used hormonal preparations for emergency contraception, levonorgestrel (LNG) and ulipristal acetate (UPA), is still not fully known, but clinical trials indicate that they act by inhibiting or delaying ovulation. LNG has a long history of use for emergency contraception, proven safety and high efficacy if administered in the preovulation period. The newest emergency contraceptive, UPA, available only with a prescription, is indicated within this period of 120 hours after sexual intercourse and the data indicate that UPA does not lose efficacy within this period. Clinical trials showed its noninferiority versus LNG and its effect on the potentially occurring pregnancy is being additionally monitored. However, many misconceptions and controversial opinions about emergency contraception are still present, even among pharmacists. A search of Medline database identified 20 papers published from January 1993 to December 2012, on pharmacists’ knowledge, attitudes and practices related to emergency contraception. In these papers, the attitudes of pharmacists pertaining to the dispensing regime of emergency contraception were different. Research in Australia has shown that personal attitudes and religious convictions influence the practice of dispensing emergency contraception. In the research conducted in New Mexico, 30% of pharmacists were against prescribing emergency contraception for religious or moral reasons. There were no published data in regards to pharmacists’ knowledge, attitudes and dispensing practice in Serbia and such research is highly recommended.
1. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomized trial. Lancet 1999; 353: 697-702. http://dx.doi.org/10.1016/S0140-6736(98)07190-6
2. World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation. Randomized controlled trial of levonorgestrel versus Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352: 428-33. http://dx.doi.org/10.1016/S0140-6736(98)05145-9
3. von Hertzen H, Piaggio G, Van Look PF. Emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998; 352: 1939. http://dx.doi.org/10.1016/S0140-6736(05)60440-0
4. Cheng L, Gulmezoglu AM, Piaggio G et al. Interventions for emergency contraception. Cochrane Database Syst Rev 2008: CD001324.
5. Gemzell-Danielsson K. Mechanism of action of emergency contraception. Contraception 2010; 82: 404-9. http://dx.doi.org/10.1016/j.contraception.2010.05.004
6. Glasier AF, Cameron ST, Fine PM et al. Uliprisat acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis. Lancet 2010; 375: 555-62. http://dx.doi.org/10.1016/S0140-6736(10)60101-8
7. ICEC. International Consortium for Emergency Contraception. http://www.cecinfo.org/ (accessed December 17, 2013).
8. Richman A, Daley E, Baldwin J et al. The role of pharmacists and emergency contraception: are pharmacists' perceptions of emergency contraception predictive of their dispensing practices? Contraception 2012; 86: 370-5. http://dx.doi.org/10.1016/j.contraception.2012.01.014
9. Marions L, Cekan C, Bygdeman M, Gemzell Danielsson K. Preovulatory treatment with mifepristone and levonorgestrel impairs luteal function. Contraception 2004; 69: 373-7. http://dx.doi.org/10.1016/j.contraception.2003.11.018
10. Hapangama DK, Glasier AF, Baird DT. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. Contraception 2001; 63: 123-9. http://dx.doi.org/10.1016/S0010-7824(01)00186-X
11. Durand M, del Carmen Cravioto M, Raymond EG et al. The mechanism of action of short-term levonorgestrel administration in emergency contraception. Contraception 2001; 64: 227-34. http://dx.doi.org/10.1016/S0010-7824(01)00250-5
12. ALiMS. Ellaone: Summary of product characteristics. 2010. http://www.alims.gov.rs/ciril/files/lekovi/smpc/4451-2010-12.pdf (in Serbian) (accessed July 03, 2013).
13. Brache V, Cochon L, Jesam C et al. Immediate preovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod 2010; 25: 2256-63. http://dx.doi.org/10.1093/humrep/deq157
14. Watson Pharma, Inc. Ella (ulipristal) package insert. Morristown, NJ; 2010.
15. Gemzell-Danielsson K. Mechanism of action of emergency contraception. Contraception 2010; 82: 404-9. http://dx.doi.org/10.1016/j.contraception.2010.05.004
16. Stratton P, Hartog B, Hajizadeh N et al. Endometrial effects of a single early-luteal dose of the selective progesterone receptor modulator CDB-2914. Hum Reprod 2000; 15: 1092-9. http://dx.doi.org/10.1093/humrep/15.5.1092
17. American College of Obstetricians and Gynecologists. Emergency contraception: practice bulletin no. 112. Obstet Gynecol 2010; 115: 1100-9. http://dx.doi.org/10.1097/AOG.0b013e3181deff2a
18. Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999; 353: 721. http://dx.doi.org/10.1016/S0140-6736(98)05718-3
19. Fine P, Mathe H, Ginde S et al. Ulipristal acetate taken 48-120 hours after inter-course for emergency contraception. Obstet Gynecol 2010; 115: 257-63. http://dx.doi.org/10.1097/AOG.0b013e3181c8e2aa
20. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. FSRH Guidance (August 2011) Emergency Contraception. http://www.fsrh.org/pdfs/CEUguidanceEmergencyContraception11.pdf (accessed July 03, 2013).
21. ALiMS. Escapelle: Summary of product characteristics. 2008. http://www.alims.gov.rs/ciril/files/lekovi/smpc/4508-2008-12.pdf (in Serbian) (accessed on July 03, 2013).
22. Shrader S, Hall L, Ragucci K, Rafie S. Updates in Hormonal Emergency Contraception. Pharmacotherapy 2011; 31(9): 887-95. http://dx.doi.org/10.1592/phco.31.9.887
23. Halpern V, Raymond EG, Lopez LM. Repeated use of pre-and postcoital hormonal contraception for prevention of pregnancy. Cochrane Syst Rev 2010; 1:CD00 7595.
24. Hariparsard N. Attitudes and practices of pharmacists towards emergency contraception in Durban, South Africa. Eur J Contracept Reprod Health Care 2001; 6: 87 -92. http://dx.doi.org/10.1080/713604207
25. Barrett G, Harper R. Health professionals’ attitudes to the deregulation of emergency contraception (or the problem of female sexuality). Sociol Health Illness 2000; 22: 197-216. http://dx.doi.org/10.1111/1467-9566.00199
26. Aneblom G, Stalsby Lundborg C, Carlsten A et al. Emergency contraceptive pills over-the-counter: practices and attitudes of pharmacy and nurse-midwife providers. Patient Education and Counseling 2004; 55: 129-35. http://dx.doi.org/10.1016/j.pec.2003.08.008
27. Hussainy S, Stewart K, Chapman C et al. Provision of the emergency contraceptive pill without prescription: attitudes and practices of pharmacists in Australia. Contraception 2011; 83: 159-66. http://dx.doi.org/10.1016/j.contraception.2010.07.001
28. Apikoglu-Rabus S, Martin Clark P, Izzettin F. Turkish pharmacists’ counseling practices and attitudes regarding emergency contraceptive pills. Int J Clin Pharm 2012; 34: 579-86. http://dx.doi.org/10.1007/s11096-012-9647-x
29. Borrego M, Short J, House N et al. New Mexico Pharmacists’ Knowledge, Attitudes, and Beliefs Toward Prescribing Oral Emergency Contraception. J Am Pharm Assoc 2006; 46: 33-43. http://dx.doi.org/10.1331/154434506775268634